^
Association details:
| Biomarker: | FOXA1 mutation |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug Class: | Aromatase inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
NG05 - Epigenetic mechanisms of endocrine therapy response in breast cancer
Published date:
03/10/2021
Excerpt:
FOXA1 mutations were associated with a lower response to aromatase inhibitors in breast patient samples...FOXA1 and ARID1A mutations are associated with worse outcome to endocrine therapy and position these genetic alterations as potential biomarkers of endocrine therapy response for the treatment of metastatic ER+ breast cancer.
